Inside Moderna and Merck’s Cancer Vaccine Breakthrough

In a milestone for medical research, Moderna and Merck & Co. announced that their personalized mRNA cancer vaccine achieved success in a late-stage clinical trial. The outcome marks the first positive late-stage trial result for a therapeutic cancer vaccine after more than a century of failed attempts across the medical field.

A Landmark Breakthrough in Cancer Treatment

The investigational therapy, known as intismeran autogene (also referred to as V940 or mRNA-4157), was tested in a Phase 3 study named INTerpath-001. The trial enrolled 1,137 patients with completely resected stage IIB-IV cutaneous melanoma. Participants were randomly assigned in a 2:1 ratio to receive the personalized vaccine combined with Merck’s established immunotherapy drug, pembrolizumab (widely known as Keytruda), or to receive pembrolizumab alone.

According to the companies, the combination met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival, reducing the risk of cancer recurrence and spread compared to Keytruda alone. Cancer experts hailed the development as the beginning of an era of custom-made vaccines designed to train the immune system to fight an individual patient’s specific cancer.

How the Personalized mRNA Vaccine Works

Unlike traditional vaccines used to prevent infectious diseases, the Moderna-Merck treatment is a therapeutic vaccine designed for patients who already have cancer. Its goal is to stop the disease from returning or spreading after surgical removal of tumors.

Photo: channelnewsasia.com

Moderna and Merck Announce Major Breakthrough in mRNA Cancer Vaccine Trial

The treatment process begins by genetically analyzing a sample of a patient’s tumor after surgery to identify mutations that are present in the cancer but absent in normal cells. These mutations produce abnormal proteins or protein fragments called neoantigens, which act as molecular flags distinguishing cancer cells from healthy tissue. Using mRNA technology, the vaccine carries genetic instructions targeting these unique mutations to teach the patient’s immune system—particularly T cells—to recognize and destroy the cancer cells.

By combining the vaccine with pembrolizumab, the therapy pairs two complementary strategies: the vaccine teaches the immune system what targets to look for, while pembrolizumab removes the biological brakes that can prevent immune cells from attacking.

A Decade-Long Collaboration and Skepticism Overcome

The breakthrough is the result of a 10-year partnership between Moderna and Merck. The companies initially formed a separate vaccine venture before establishing their cancer collaboration in 2016, a deal in which Merck paid $200 million upfront, followed by another $250 million in 2022.

Photo: Reuters

Moderna’s First mRNA-359 Personalized Cancer Vaccine Commemorative Vial

Despite the eventual success, the treatment faced deep skepticism from investors and industry observers. At an off-site leadership meeting held by Moderna in March 2023—following promising mid-stage data—CEO Stéphane Bancel asked executive staff if any of the roughly 100 leaders present had expected the experimental treatment to succeed. When prompted to stand, even Moderna’s president, Stephen Hoge, remained seated, later recalling that none of them truly believed it at first.

Long-term data supporting the approach have accumulated over time. Five-year follow-up data from an earlier mid-stage trial showed that adding the vaccine to Keytruda cut the risk of cancer returning or death by 49% compared with Keytruda alone, while reducing the risk of distant metastasis or death by 59%.

Immunotherapy effective against rare subtype of advanced melanoma

Regulatory Path and Future Outlook

While the Phase 3 readout has generated enthusiasm on Wall Street and caused shares of both companies to rise, full trial details are still pending presentation at an upcoming medical meeting. Experts and observers emphasize caution until full data are officially released and reviewed by regulators.

Regulatory filings are now beginning, meaning official approval, pricing, and reimbursement decisions remain ahead. Each custom-made vaccine produced for the clinical trials took six to eight weeks to manufacture, introducing logistical and cost burdens that could influence how quickly the therapy reaches patients outside major research hospitals. Nevertheless, industry estimates suggest that the treatment could realistically reach patients within the next two years pending successful regulatory review.

Building on these results, the companies are already running additional trials evaluating the same vaccine-Keytruda combination across several other tumor types, including lung, bladder, kidney, pancreatic, and stomach cancers.